Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
Titel:
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
Auteur:
Zanghì, Aurora Avolio, Carlo Signoriello, Elisabetta Abbadessa, Gianmarco Cellerino, Maria Ferraro, Diana Messina, Christian Barone, Stefania Callari, Graziella Tsantes, Elena Sola, Patrizia Valentino, Paola Granella, Franco Patti, Francesco Lus, Giacomo Bonavita, Simona Inglese, Matilde D’Amico, Emanuele